Skip to content

CEREBAIN BIOTECH CORP.: 10-Q filed 2017-05-11

What CEREBAIN BIOTECH CORP. reported in its quarterly report filed 2017-05-11 (fiscal Q3 2017): 22 published measures, 57 facts as tagged in accession 0001477932-17-002177.

This filing

Form
10-Q (quarterly report)
Filed
2017-05-11
Fiscal period
fiscal Q3 2017
Accession
0001477932-17-002177 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All CEREBAIN BIOTECH CORP. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-03-31403,285USD
At 2016-06-30495,944USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2017-03-314,282,536USD
At 2016-06-303,540,708USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-03-31-3,879,251USD
At 2016-06-30-3,044,764USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2017-03-31517USD
At 2016-06-3020,245USD
At 2016-03-312,773USD
At 2015-06-30486USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-01-01 to 2017-03-31-566,754USD90
2016-07-01 to 2017-03-31-15,449,535USD274
2016-01-01 to 2016-03-31-495,484USD91
2015-07-01 to 2016-03-31-1,568,716USD275

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2016-07-01 to 2017-03-31-445,728USD274
2015-07-01 to 2016-03-31-393,613USD275

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2016-07-01 to 2017-03-31426,000USD274
2015-07-01 to 2016-03-31395,900USD275

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-03-31-26,967,642USD
At 2016-06-30-11,518,106USD

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2017-01-01 to 2017-03-317,605,236shares90
2016-07-01 to 2017-03-317,421,427shares274
2016-01-01 to 2016-03-316,378,479shares91
2015-07-01 to 2016-03-315,614,438shares275

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2016-07-01 to 2017-03-31263,792USD274
2015-07-01 to 2016-03-31245,475USD275

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-01-01 to 2017-03-31-524,584USD90
2016-07-01 to 2017-03-31-1,542,910USD274
2016-01-01 to 2016-03-31-424,805USD91
2015-07-01 to 2016-03-31-1,312,290USD275

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-03-31403,285USD
At 2016-06-30495,944USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2017-01-01 to 2017-03-3140,226USD90
2016-07-01 to 2017-03-31116,476USD274
2016-01-01 to 2016-03-3126,697USD91
2015-07-01 to 2016-03-3197,717USD275

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-03-311,509,958USD
At 2016-06-301,092,230USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2017-03-31908,839USD
At 2016-06-30685,045USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2017-01-01 to 2017-03-31524,584USD90
2016-07-01 to 2017-03-311,542,910USD274
2016-01-01 to 2016-03-31424,805USD91
2015-07-01 to 2016-03-311,312,290USD275

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2017-01-01 to 2017-03-31439,052USD90
2016-07-01 to 2017-03-311,267,759USD274
2016-01-01 to 2016-03-31397,465USD91
2015-07-01 to 2016-03-311,123,910USD275

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2017-01-01 to 2017-03-3158,902USD90
2016-07-01 to 2017-03-31190,369USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-03-317,710,347shares
At 2016-06-307,116,347shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2017-03-3123,080,681USD
At 2016-06-308,466,226USD

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2016-07-01 to 2017-03-3150,000USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2016-07-01 to 2017-03-31253,829USD274
2015-07-01 to 2016-03-31532,331USD275

Inspect the source

Entity
CEREBAIN BIOTECH CORP. / CIK 0001453099
Captured
SEC response SHA-256
9fdf4c3b2bb6536cc10c8e24af596aaa762e0560a25fd29c07e252f58d07262f

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001453099.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))